Intracellular loops 3–9, a pepducin modulator of Gs-biased ß2AR signaling, has been shown to be a potential asthma therapy candidate as ß-arrestins are believed to be responsible for the symptoms associated with asthma (Walker et al., 2003; Dickey et al., 2010; Thanawala et al., 2013; Carr et al., 2014; Lin et al., 2018). Here, SAG is linked to asthma.